Quest Diagnostics Incorporated (NYSE:DGX – Get Free Report) CAO Michael Deppe sold 11,776 shares of the company’s stock in a transaction that occurred on Friday, November 13th. The stock was sold at an average price of $260.17, for a total transaction of $3,063,761.92. Following the completion of the transaction, the chief accounting officer owned 35,203 shares of the company’s stock, valued at approximately $9,158,764.51. The trade was a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Quest Diagnostics Price Performance
Shares of DGX traded up $2.07 during midday trading on Monday, hitting $261.67. 734,851 shares of the company traded hands, compared to its average volume of 975,934. Quest Diagnostics Incorporated has a 52 week low of $171.18 and a 52 week high of $263.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.58 and a current ratio of 1.70. The firm has a 50 day moving average of $241.23 and a 200-day moving average of $215.58. The stock has a market cap of $28.79 billion, a price-to-earnings ratio of 26.06, a PEG ratio of 2.32 and a beta of 0.54.
Quest Diagnostics (NYSE:DGX – Get Free Report) last announced its earnings results on Thursday, October 22nd. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.87 by $0.13. Quest Diagnostics had a return on equity of 16.21% and a net margin of 9.53%. The business had revenue of $3.10 billion during the quarter, compared to analyst estimates of $3.05 billion. During the same quarter in the previous year, the business earned $2.60 earnings per share. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. On average, analysts forecast that Quest Diagnostics Incorporated will post 11.29 EPS for the current fiscal year.
Quest Diagnostics Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 27th. Investors of record on Tuesday, January 12th will be issued a dividend of $0.86 per share. This represents a $3.44 annualized dividend and a yield of 1.3%. The ex-dividend date of this dividend is Tuesday, January 12th. Quest Diagnostics’s dividend payout ratio (DPR) is 34.26%.
Hedge Funds Weigh In On Quest Diagnostics
Institutional investors have recently made changes to their positions in the business. BlackRock Inc. bought a new position in Quest Diagnostics in the 2nd quarter worth about $1,965,923,000. EdgePoint Investment Group Inc. grew its holdings in shares of Quest Diagnostics by 35.1% during the 1st quarter. EdgePoint Investment Group Inc. now owns 2,243,869 shares of the medical research company’s stock valued at $439,753,000 after acquiring an additional 582,797 shares in the last quarter. Bank of America Corp DE bought a new position in Quest Diagnostics during the second quarter valued at approximately $410,151,000. Dimensional Fund Advisors LP lifted its holdings in Quest Diagnostics by 0.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,949,535 shares of the medical research company’s stock worth $382,085,000 after purchasing an additional 17,987 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Quest Diagnostics by 11.3% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 942,407 shares of the medical research company’s stock valued at $199,743,000 after buying an additional 95,804 shares during the last quarter. 88.06% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several equities analysts have recently weighed in on the company. Argus set a $260.00 target price on Quest Diagnostics in a research report on Wednesday, July 29th. Mizuho increased their target price on shares of Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Weiss Ratings upgraded Quest Diagnostics from a “buy (a)” rating to a “buy (a+)” rating in a report on Wednesday, October 21st. Wall Street Zen raised Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Tuesday, July 28th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Quest Diagnostics from $220.00 to $250.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, Quest Diagnostics currently has an average rating of “Moderate Buy” and an average target price of $248.70.
View Our Latest Analysis on Quest Diagnostics
About Quest Diagnostics
Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.
Featured Stories
- Five stocks we like better than Quest Diagnostics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
